GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE19738 Query DataSets for GSE19738
Status Public on Oct 05, 2011
Title Major Depressive Disorder blood gene expression
Organism Homo sapiens
Experiment type Expression profiling by array
Summary Background: Major Depressive Disorder (MDD) is a moderately heritable disorder with a high lifetime prevalence. At present, laboratory blood tests to support MDD diagnosis are not available.

Methods: We used a classifier approach on blood gene expression profiles of a unique set of non-medicated subjects (MDD patients and controls) to select genes of which expression is predictive for disease status. To reveal blood gene expression changes related to MDD disease, we applied a powerful ex vivo stimulus to the blood, i.e. incubation with lipopolysaccharide (LPS; 10 ng/ml blood).

Results: Based on LPS-stimulated blood gene expression using whole-genome microarrays in 42 subjects (primary cohort; 21 MDD patients (mean age 42.3 years), 21 healthy controls (mean age 41.9 years)), we identified a set of genes (CAPRIN1, CLEC4A, KRT23, MLC1, PLSCR1, PROK2, ZBTB16) that serves as a molecular signature of MDD. These findings were validated for the primary cohort using an independent quantitative PCR method (P = 0.007). The difference between depressive patients and controls was confirmed (P = 0.019) in a replication cohort of 13 patients with MDD (mean age 42.8 years) and 14 controls (mean age 45.6 years). The MDD-signature score comprised of expression levels of 7 genes could discriminate depressive patients from controls with sensitivity of 76.9% and specificity of 71.8%.

Conclusions: We show for the first time that molecular analysis of stimulated blood cells can be used as an endophenotype for MDD diagnosis, which is a milestone in establishing biomarkers for neuropsychiatric disorders with moderate heritability in general. Our results may provide a new entry point for following and predicting treatment outcome, as well as prediction of severity and recurrence of MDD.
Overall design In total, 33 MDD patients and 34 healthy controls were analyzed using basal gene expression in whole blood, and gene expression from whole blood that was stimulated with LPS for 5-6 h, using microarrays.

Patients were arbitrarily selected from all patients to serve as primary cohort (nMDD = 21 (MDD01-MDD21); nControls = 21 (Con01-Con21)), or replication cohort (nMDD = 12 (MDD22-MDD35); nControls = 13 (Con22-Con37)) using microarrays.

This submission does not include Samples CON21_LPS or CON30_LPS.
Contributor(s) Spijker S, van Zanten JS, de Jong S, Penninx BW, van Dyck R, Zitman FG, Smit JH, Zitman FG, Ylstra B, Smit AB, Hoogendijk WG
Citation(s) 20471630
Submission date Jan 04, 2010
Last update date Sep 01, 2015
Contact name sabine Spijker
Organization name Neuroscience Campus Amsterdam
Department Center for Neurogenomics and Cognitive Research
Street address De Boelelaan 1085
City Amsterdam
ZIP/Postal code 1081HV
Country Netherlands
Platforms (1)
GPL6848 Agilent-012391 Whole Human Genome Oligo Microarray G4112A (Probe Name version)
Samples (132)
GSM492850 whole blood-control-basal-CON01
GSM492851 whole blood-control-basal-CON02
GSM492852 whole blood-control-basal-CON03
BioProject PRJNA122201

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE19738_RAW.tar 1.6 Gb (http)(custom) TAR (of TXT)
Raw data provided as supplementary file
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap